Analysts' ratings for Allstate ALL over the last quarter vary from bullish to bearish, as provided by 14 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 5 | 2 | 2 | 0 |
Last 30D | 0 | 0 | 1 | 1 | 0 |
1M Ago | 3 | 3 | 0 | 0 | 0 |
2M Ago | 1 | 1 | 0 | 0 | 0 |
3M Ago | 1 | 1 | 1 | 1 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $177.64, a high estimate of $200.00, and a low estimate of $145.00. This current average has increased by 10.6% from the previous average price target of $160.62.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Allstate is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Elyse Greenspan | Wells Fargo | Raises | Underweight | $146.00 | $145.00 |
Oliver Wintermantel | Evercore ISI Group | Raises | In-Line | $173.00 | $166.00 |
Meyer Shields | Keefe, Bruyette & Woods | Raises | Outperform | $189.00 | $181.00 |
Jimmy Bhullar | JP Morgan | Raises | Overweight | $185.00 | $172.00 |
Harry Fong | Roth MKM | Raises | Buy | $200.00 | $175.00 |
Paul Newsome | Piper Sandler | Raises | Overweight | $188.00 | $172.00 |
Vikram Gandhi | HSBC | Announces | Buy | $190.00 | - |
Alex Scott | Goldman Sachs | Raises | Buy | $195.00 | $164.00 |
Meyer Shields | Keefe, Bruyette & Woods | Raises | Outperform | $181.00 | $171.00 |
Brian Meredith | UBS | Raises | Buy | $185.00 | $171.00 |
Elyse Greenspan | Wells Fargo | Raises | Underweight | $145.00 | $112.00 |
Jimmy Bhullar | JP Morgan | Raises | Overweight | $172.00 | $164.00 |
C. Gregory Peters | Raymond James | Raises | Strong Buy | $180.00 | $155.00 |
Michael Zaremski | BMO Capital | Raises | Market Perform | $158.00 | $140.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Allstate. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Allstate compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Allstate's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Allstate's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Allstate analyst ratings.
Discovering Allstate: A Closer Look
Allstate is one of the largest U.S. property and casualty insurers in the U.S. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 company agencies.
A Deep Dive into Allstate's Financials
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Allstate showcased positive performance, achieving a revenue growth rate of 8.68% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Allstate's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 9.84%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Allstate's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Allstate's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.43%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Allstate's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.5, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
How Are Analyst Ratings Determined?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.